{'fraction_non_alphanumeric': 0.03305785123966942, 'fraction_numerical': 0.003305785123966942, 'mean_word_length': 6.481481481481482, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New intermediate‐stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization

The need for a subclassification of Barcelona Clinic Liver Cancer (BCLC) intermediate‐stage (BCLC B) has arisen because of its diversity. We evaluated the prognostic capability of the BCLC B subclassification proposed by Bolondi et al. in patients treated with transarterial chemoembolization (TACE). Furthermore, we introduce a new subclassification for intermediate‐stage hepatocellular carcinoma (HCC) by using a new parameter related to tumour burden (up‐to‐11 criteria).